Maravai Lifesciences Holdings (MRVI) Amortization of Goodwill (2024 - 2025)

Maravai Lifesciences Holdings' (MRVI) quarterly Amortization of Goodwill came in at $30.4 million in Q2 2025, down 81.71% quarter-over-quarter from $166.2 million in Q4 2024.

Maravai Lifesciences Holdings (MRVI) Amortization of Goodwill (2024 - 2025) Analysis & Trends

Maravai Lifesciences Holdings' Amortization of Goodwill history runs 2 years deep, the most recent figure standing at $30.4 million for Q2 2025.

  • On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $30.4 million in Q2 2025; TTM through Sep 2025 was $196.6 million, a 27.46% increase from a year earlier, with the FY2024 full-year figure at $166.2 million, changed N/A from the prior year.
  • Amortization of Goodwill retreated to $30.4 million in Q2 2025 per MRVI's latest filing, from $166.2 million in the prior quarter.
  • Across five years, Amortization of Goodwill topped out at $166.2 million in Q4 2024 and bottomed at $30.4 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Maravai Lifesciences Holdings 1.03 Bn 1.02 Bn 33.70 Mn

Historic Data

Download Data
DateValue
Jun 30, 2025 30.40 Mn
Jun 30, 2025 30.40 Mn
Dec 31, 2024 166.20 Mn
Dec 31, 2024 166.20 Mn
Sep 30, 2024 154.24 Mn
Sep 30, 2024 154.24 Mn